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Redoxactive oxygen intermediate (ROI) generation during infection that plays an
important role in growth. We have examined the importance of ROI during lymphocytic choriomeningitis
virus (LCMV) infection of immortalized BHK-21 cells and murine peritoneal macrophages. Within 15 min of
virus addition, intracellular ROI levels increased. To examine the contribution of ROI to LCMV infection, cells
were pretreated with antioxidant prior to virus addition. Antioxidant treatment inhibited low and high MOI
growth of virus. The requirement for ROI was greatest during the initial phase of infection, as antioxidant
treatment after 6 h post infection had a weaker inhibitory effect. Furthermore, antioxidant treatment of cells
inhibited virus binding, while treatment of virus stocks with N-ethyl malemide, which blocks free thiols,
eliminated infectious virus. This illustrates that ROI are critical to the regulation of virus binding and growth
and has important implications for understanding the infectivity of related viruses.
© 2008 Elsevier Inc. All rights reserved.IntroductionLymphocytic choriomeningitis virus (LCMV) is an enveloped,
prototypical virus of the Arenaviridae family that is characterized by
its bisegmented negative strand RNA genome (Fenner, 1976; Meyer et
al., 2002). LCMV research has provided critical insight into complex
host-virus interactions that has been applied to related clinical human
hemorrhagic fevers (HF) such as Lassa fever (Buchmaier et al. 2001;
Cao et al., 1998; Geisbert and Jahrling, 2004; Meyer et al., 2002). HF
arenaviruses are considered a category A potential bioterrorism mi-
crobial weapon due to their severe morbidity, high mortality, and the
absence of an effective vaccine (Borio et al., 2002). In addition, LCMV
has recently been documented as a potential contaminating pathogen
in organ transplants that, combined with immunosuppression, can
lead to complications such as renal failure and seizures (Fischer et al.,
2006). The shared morphology and structure among these arena-
viruses emphasize the importance of studying LCMV infection as a
model of acute arenavirus disease. Understanding the mechanisms
regulating arenavirus infection is essential for designing new vaccine
and therapeutic strategies.
Viral infection is often accompanied by increased reactive oxygen
intermediate (ROI) generation (Baruchel and Wainberg, 1992; Casolaione; IRF, interferon regulatory
n-TBAP, Mn (III) tetrakis (4-
; NEM, N-ethyl malemide; NF-
iates; STAT, signal transducers
anscription.
).
l rights reserved.et al., 2001; Korenaga et al., 2005; Peterhans, 1997; Waris et al., 2005).
For example, inﬂuenza virus can stimulate ROI production by
polymorphonuclear leukocytes, which enhances infectivity of the
virus (Peterhans et al., 1987). Increased ROI can lead to inactivation of
anti-proteases on the surface of alveoli and therefore promote
cleavage of the precursor glycoprotein, HA0, into the infectious HA1/
HA2 form (Kido et al., 1993; Peterhans, 1997). Furthermore, ROI are
essential to inﬂuenza virus spread as glutathione (GSH) treatment of
infected mice can signiﬁcantly reduce viral titers in the lung and
trachea (Cai et al., 2003). A similar requirement for ROI in viral entry
has been demonstrated through inhibition of thiol/disulﬁde exchange
in human immunodeﬁciency virus (HIV), Newcastle disease virus, and
hepatitis virus (Abell and Brown, 1993; Abou-Jaoude and Sureau,
2007; Fenouillet et al., 2001; Jain et al., 2007; Markovic et al., 2004). In
these examples, thiol modiﬁcation facilitates protein folding and
fusion of the virus and cell membranes.
Reactive oxygen intermediates have also been shown to promote
viral replication and immunosuppression. In the case of HIV, earlier
reports demonstrate that in vitro induction of oxidative stress can
promote viral replication (Baruchel and Wainberg, 1992; Beck, 1998;
Staal et al., 1990). Additionally, infection by the virus is associated
with decreased levels of GSH and increased production of ROI
(Ciriolo et al., 1997; Garaci et al., 1997; Palamara et al., 1995). The
viral TAT protein increases intracellular ROI levels by inhibiting the
antioxidant enzyme manganese superoxide dismutase (MnSOD)
(Flores et al., 1993). ROI can then activate HIV-LTR transcription
through NF-kB as well as contribute to apoptosis of CD4+ T cells
(Buttke and Sandstrom,1994; Gulow et al., 2005; Israel and Gougerot-
Pocidalo, 1997; Israel et al., 1992; Sandstrom et al., 1993; Westendorp
et al., 1995).
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ROI during viral infection. As early as 1977, Brugh demonstrated that
the antioxidant BHT protected chickens against the lethal effects of
Newcastle disease (Brugh, 1977). Recently, antioxidant treatment of
HIV infected CD4+ T cells has been shown to restore cell proliferation
and decrease HIV replication (Baba, 2004; Cayota et al., 1996). These
results have been replicated in a murine AIDS model as pro-GSH
molecules reduced viral load in the spleen and lymph nodes
(Fraternale et al., 2008). In the case of hepatitis C virus (HCV), Izzo
et al. have reported that pharmacological reduction of nitric oxide
synthesis can reduce virus titers in HCV-serotype 1b patients (Izzo
et al., 2007).
Although multiple studies demonstrate an important role for ROI
in initiating viral entry and enhancing infectivity, it is unclear if they
are promoted and utilized by LCMV. Our results demonstrate that
LCMV induces ROI generation that is critical for optimal infection.
Antioxidant treatment of cells inhibited low and high MOI growth of
virus in immortalized BHK-21 cells and in primary cultures of mu-
rine peritoneal macrophages. The requirement for ROI was greatest
during the initial phase of infection as antioxidant treatment after
6 h post infection had a weaker inhibitory effect. Incubation of virus
with antioxidant did not induce a signiﬁcant difference in infectivity
during the standard hour infection. Instead, antioxidant treatment of
cells inhibited virus binding. In addition, treatment of virus with N-Fig. 1. BHK-21 cells increase DCFDA oxidation following LCMV infection. BHK-21 cells
were infected at anMOI of 10 for the indicated time followed by incubationwith DCFDA.
(A) Representative histogram of the percentage of infected cells at 24 h post infection as
determined by intracellular staining utilizing anti-LCMV-NP antibody 113. (B) The
DCFDA ﬂuorescence at 15 min after mock treatment or addition of LCMV is plotted as a
histogram compared to cells at t=0. (C) Data are represented as the percent increase in
DCFDA MFI compared to t=0 cells with the average and standard deviation shown.
Three to six samples were analyzed in three independent experiments. ⁎, Signiﬁcant
difference between untreated and treated samples; p≤0.05.ethyl malemide (NEM), which blocks free thiols, eliminated infec-
tious virus and provides evidence that ROI may promote thiol
disulﬁde exchange between the virus and the cell. Together, these
data suggest that ROI are required for LCMV binding and subsequent
productive infection. The events surrounding LCMV infection are
germane to understanding the binding and growth of clinically
relevant areanviruses.
Results
LCMV infection of BHK-21 ﬁbroblast cells induces ROI production
There are multiple studies demonstrating that reactive oxygen
intermediate (ROI) production is associated with infection by viral
pathogens such as respiratory syncytial virus (RSV), vesicular
stomatitis virus (VSV), HIV, and HCV (Baruchel and Wainberg, 1992;
Casola et al., 2001; Riva et al., 2006). To determine whether the
arenavirus Lymphocytic Choriomeningitis Virus (LCMV) induced ROI
production during infection, DCFDA oxidation was measured in BHK-
21 ﬁbroblasts following virus infection. DCFDA is a cell permeant dye
that is non-ﬂuorescent until being oxidized by peroxides, peroxyni-
trite, and/or hydroxyl radicals. Oxidation increases the ﬂuorescence of
the dye, which can be recorded by ﬂow cytometry. To insure a high
efﬁciency of infection, cells were exposed to virus at anMOI of 10. This
resulted in 90±2.6% of cells being infected by 24 h (Fig. 1A). As a
control, samples were also mock infected to ensure that the procedure
did not induce ROI production. Within 15 min of virus addition, there
was a two-fold increase in DCFDA oxidation compared to the starting
point and mock infected control (Fig. 1B). This increase in ROI was
similar to previously published values following RSV infection as well
as growth factor receptor stimulation (Casola et al., 2001; Lassegue
et al., 2001; May and de Haen, 1979). By 30 min post infection, ROI
levels had declined, but were still elevated above mock treated
samples. A second increase in ROI levels was observed at 1 h following
infection prior to declining to mock treated levels within 2 h (Figs. 1B,
1C). As a control for DCFDA oxidation, cells exposed to 200 µM
hydrogen peroxide for 15 min also exhibited a signiﬁcant increase
over unstimulated cells (data not shown). These results demonstrate
that ROI are produced following LCMV infection.
MnTBAP pretreatment of BHK-21 cells results in reduced LCMV titers
following infection
Understanding that ROI are generated during LCMV infection
prompted us to examine whether decreasing the production of ROI
would alter viral infection. To determine the requirement of ROI
during LCMV infection, we cultured BHK-21 ﬁbroblasts with the
antioxidant Mn (III) tetrakis (4-benzoic acid) porphyin chloride
(MnTBAP) prior to addition of virus at an MOI of 1. MnTBAP is a
small molecule mimetic compound with superoxide dismutase-like
activity and the ability to scavenge peroxynitrite. At different times
post infection the amount of virus released in the supernatant was
quantitated by plaque assay. Fig. 2A demonstrates that 48 h post
infection, virus levels for vehicle-treated cells increased to
1.5×108 pfu/mL. In contrast, MnTBAP treatment of cells prior to infec-
tion resulted in a concentration dependent inhibition in virus growth.
In the presence of 10 µM MnTBAP, viral production was decreased 82-
fold compared to vehicle samples during the ﬁrst 48 h of infection. As
the concentration was increased to 50 µM, only ∼8×102 pfu/mL of
virus was measured in the supernatant. When cells were pretreated
with 200 µM MnTBAP, virus levels were below the limit of detection
for the duration of the experiment (96 h). As theMOIwas decreased to
0.1, to observemultiple step growth, a similar trendwas also observed.
Within 24 h of viral infection, virus levels were below the limit of
detection in cultures treatedwith 200 µMMnTBAP (Fig. 2B). At anMOI
of 10, the viral titer reached 2.6×102 pfu/mL in the presence 200 µM
Fig. 2.MnTBAP pretreatment of BHK-21 cells results in decreased LCMV virus titers. BHK-21 cells were pretreatedwithMnTBAP or vehicle for 1 h prior to virus addition. (A) Cells were
treated with increasing concentrations of MnTBAP prior to addition of virus at an MOI of 1. (B, C) Cells were pretreated with 200 µMMnTBAP prior to addition of virus at an MOI of 0.1
(B) or 10 (C). At each time point, supernatants were titered for infectious virus. Five samples were analyzed in a total of three independent experiments. ⁎, Signiﬁcant difference
between vehicle- and antioxidant-treated samples; p≤0.05.
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(Fig. 2C). At later time points, virus growth was undetectable in the
presence of the antioxidant. Thus, ROI are required for productive
LCMV Armstrong infection of cultured cells.
Ebselen and NAC pretreatment of BHK-21 cells results in reduced LCMV
titers following infection
Previous studies of RSV infection have shown that the antioxidant
BHA did not diminish the release of infectious virus (Casola et al.,
2001). Therefore, to eliminate the possibility that decreased viral
growth resulted from a different mechanism of action by MnTBAP,
BHK-21 cells were infected in the presence of the antioxidants Ebselen
or N-Acetyl-cysteine (NAC). Ebselen acts as a glutathione peroxidase,
peroxiredoxin mimic, and a scavenger of peroxynitrite. NAC promotes
the generation of cysteine and indirectly increases glutathione levels.
Similar to the results with MnTBAP, pretreatment of cells with 20 µM
Ebselen signiﬁcantly reduced viral production following infection atFig. 3. Ebselen and NAC pretreatment of BHK-21 cells results in reduced LCMV titers following
addition. (A) Cells were pretreated for 1 h with 20 µM Ebselen prior to infectionwith LCMV at
an MOI of 1. At each time point, supernatants were titered for infectious virus. Four samp
vehicle- and antioxidant-treated samples; p≤0.05.anMOI of 1 (Fig. 3A). During the initial 24 h, virus levels were over 100
fold lower than vehicle-treated samples. This trend of reduced viral
growth continued for the duration of the experiment (96 h).
NAC pretreatment had a greater inhibitory effect on virus growth
than Ebselen.When cells were infected in the presence of 10mMNAC,
virus levels were below the limit of detection when measured at 24 h
(Fig. 3B). In contrast, titers in vehicle-treated samples increased from
1.5×103 to 6.4×107 pfu/mL. Virus remained undetectable in NAC
treated cultures for the duration of the experiment (96 h). These
results demonstrate that multiple antioxidants can decrease LCMV
growth.
Reduced viral growth following antioxidant treatment is not the result of
decreased cell numbers or cell viability
To exclude the possibility that reduced viral growth following
antioxidant treatment was due to cell death, the number and
percentage of viable cells were determined following viral infection.infection. BHK-21 cells were pretreated with antioxidant or vehicle for 1 h prior to virus
anMOI of 1. (B) Cells were pretreated with 10mMNAC for 1 h prior to LCMV infection at
les were analyzed in two independent experiments. ⁎, Signiﬁcant difference between
Fig. 4. Reduced viral growth following antioxidant treatment is not the result of
decreased cell numbers or viability. (A) Viable BHK-21 cells were enumerated by trypan
blue exclusion assay. Cells were counted at either time 0 or 48 h post infection in the
presence or absence of vehicle, 200 µM MnTBAP, 10 mM NAC, or 20 µM Ebselen. (B)
Percent viable cells were determined for each condition in (A) by determining the ratio
of viable cells to total cells. Four samples were analyzed in two independent
experiments. ⁎, Signiﬁcant difference between vehicle- and antioxidant-treated
samples; p≤0.05. ns, not signiﬁcant.
Fig. 5.MnTBAP treatment of macrophages results in decreased LCMV titers following infection
were pretreated for 1 h with 200 µMMnTBAP and infected at anMOI of 0.1 (A), 1 (B), or 10 (C)
macrophages were enumerated by trypan blue exclusion assay at either time 0 or 48 h post i
two independent experiments. ⁎, Signiﬁcant difference between vehicle- and antioxidant-t
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presence or absence of 200 µM MnTBAP, 10 mM NAC, or 20 µM
Ebselen. At 48 h following infection, the number of viable cells was
determined by trypan blue exclusion. At the start of the experiment,
there were ∼1×106 viable BHK-21 cells. Within 48 h, cell numbers in
the untreated sample (mock) had increased to ∼6–8×106 viable cells
(Fig. 4A). A similar growth of cells was also observed for samples
infected in the presence of vehicle or antioxidant. To ensure that
equivalent numbers did not result from overgrowth and subsequent
death of cultures, the percent viability was determined by comparing
the number of viable cells against the total number of cells counted.
The results in Fig. 4B indicate that, with the exception of a slight
increase in cell viability for the Ebselen vehicle, there was no
signiﬁcant difference in the percentage of viable cells under each
condition. Thus, antioxidant treatment does not signiﬁcantly alter the
number of viable cells for the initial 48 h following viral infection.
MnTBAP treatment of macrophages results in decreased LCMV titers
following infection
Since BHK-21 cells are an immortalized cell line, we wanted to
determine if ROI were also required for infection of primary peritoneal
macrophages, a physiologically relevant target of LCMV. Following
infection at a MOI of 0.1, there was a stepwise increase in viral titer in
the vehicle samples during the ﬁrst 96 h of infection (Fig. 5A). Viral
growth peaked at 72 h with a maximal titer of 5×104 pfu/mL. This
value was similar to previously published studies of LCMV Armstrong
growth in peritoneal macrophages (King et al., 1990). In contrast to
vehicle-treated samples, macrophages infected in the presence of
MnTBAP did not exhibit a titer above the limit of detection for the
duration of the experiment (96 h). When theMOI was increased to 1, a
similar trend was also observed. Virus levels increased slightly above
the limit of detection in antioxidant-treated samples at 24 and 48 h,
but they only reached 2×102 pfu/mL compared to 5×104 pfu/mL in
vehicle samples (Fig. 5B). By 72 h, virus growth was again unde-. Peritoneal macrophages were isolated as described in thematerials andmethods. Cells
with LCMV. At each time point, supernatants were titered for infectious virus. (D) Viable
nfection in the presence of absence of 200 µMMnTBAP. Three samples were analyzed in
reated samples; p≤0.05.
Fig. 6. MnTBAP is less effective at reducing viral titers when added after initial infection. BHK-21 cells were infected with LCMV at an MOI of 0.1 (A), 1 (B), or 10 (C). At 6 h post
infection, 200 µM MnTBAP was added to cultures. At each time point, supernatants were titered for infectious virus. Three samples were analyzed in two independent experiments.
⁎, Signiﬁcant difference between vehicle- and antioxidant-treated samples; p≤0.05.
Fig. 7. The role of ROI and free thiols for LCMV infectivity and binding. (A) Virus stocks
were incubated with 200 µM MnTBAP or vehicle in the presence or absence of 300 mM
NEM. At each time point, virus was diluted 1000 fold, frozen at −70 °C, and titered. (B)
Cells were pretreated with 200 µM MnTBAP for 1 h prior to being placed at 4 °C. Virus
was then added at an MOI of 0.5 and the percentage of bound virus after 1 h was
determined as described in the materials and methods. Three to six samples were
analyzed in two independent experiments. ⁎, signiﬁcant difference between vehicle-
and antioxidant- or NEM-treated samples; p≤0.05.
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lower than vehicle-treated samples at 24 h (Fig. 5C). This decrease in
virus growth was evident for the duration of the experiment. To
ensure that the decrease in virus growth did not result from decreased
cell survival, the number of viable cells was measured at 48 h post
infection in the presence of MnTBAP. Fig. 5D demonstrates equivalent
cell numbers were recovered from cultures in the presence or absence
of antioxidant. Together with our previous ﬁndings, these results
indicate that ROI are required for productive infection of cultured cells
as well as ex vivo primary macrophages by LCMV.
MnTBAP is less effective at reducing viral titers when added after initial
infection
To determine the requirement of reactive oxygen intermediates
during later stages of the viral life cycle, cells were infected with LCMV
Armstrong for 6 h prior to the addition of 200 µM MnTBAP. Similar to
our previous results, vehicle treatment had minimal effects on virus
growth at an MOI of 0.1, 1, or 10. (Figs. 6A–C). At an MOI of 0.1, the
addition of MnTBAP did not signiﬁcantly decrease the viral titer
compared to the control samples at 24 h (Fig. 6A). By 48 h there was a
signiﬁcant 72-fold decrease in virus in cultures that had received
MnTBAP at 6 h post infection. However, this decrease was minimal
compared to antioxidant-pretreated cells where virus levels were
undetectable (Fig. 2B). When the MOI was increased to 1 or 10, a
similar decrease in virus growth was observed when MnTBAP was
added back to the cultures at 6 h (Figs. 6B, C). In each of these
infections, virus levels remained lower in the presence of antioxidant
than vehicle-treated samples for the duration of the experiment
(96 h). Combined with our previous results, these experiments
demonstrate that the initiation of LCMV infection is more dependent
upon ROI production than later stages of the viral lifecycle.
Incubation of LCMV with MnTBAP does not decrease virus infectivity
during the initial hour of infection
To determine if the reduced viral titers observed are due to the
oxidative environment altering the virion, virus was incubated in the
presence or absence of MnTBAP for 24 h. The amount of infectious
virus was then quantitated by plaque assay to determine if the
infectivity of the virus was altered. Fig. 7A demonstrates that there
was no signiﬁcant decrease in the viral titer in the presence or absence
of MnTBAP during the ﬁrst 2 h of incubation. After 3 h of incubation,
the titer of virus incubated with MnTBAP had dropped from 2.3×106
to about 3.5×105 compared to 1×106 in vehicle-treated stocks. After
24 h, infectious virus could not be recovered from either stock.
In order to further understand the importance of oxidative stress
to viral infectivity, we determined the consequence to infection of
masking redox sensitive thiols on the virion. LCMV was incubatedwith MnTBAP or vehicle in the presence or absence of the alkylator N-
ethyl malemide (NEM). NEM irreversibly alkylates free thiol residues.
This interaction would prevent subsequent oxidation or disulﬁde
bond formation by the thiol. Within 10 min of NEM incubation,
regardless of time with antioxidant, viral infectivity was undetectable
(t=0) (Fig. 7A). Infectious virus was unable to be recovered for the
duration of the experiment (24 h). These results indicate that
although there is a slight loss over time, incubation of virus with
antioxidant does not signiﬁcantly alter the initial infectivity of the
virus. However, there is a necessity for free thiols on the virion to
facilitate productive infection.
MnTBAP pretreatment of BHK-21 cells inhibits LCMV Armstrong binding
Our earlier results indicate that ROI generated in response to the
addition of virus have the largest impact during the initial stages of
infection. The above data also indicate that free thiol residues must be
present on the virus to promote productive infection. To determine if
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of the cell and the virus, a LCMV binding assay was performed as
previously described (de la Torre et al., 1993). Brieﬂy, cells were
infected with LCMV in the presence or absence of MnTBAP at 4 °C for
1 h. Unbound virus was then removed by cold PBS wash of the
monolayer. Cells were then homogenized and debris was removed
prior to measurement of viral titer by plaque assay. Fig. 7B demons-
trates that antioxidant treatment signiﬁcantly inhibited (19%(vehicle)
vs. 2%(MnTBAP-treated)) the binding of LCMV to the cell surface.
Together, these results indicate that ROI generated in response to
LCMV are important for the binding and subsequent growth of virus.
Discussion
In this study, we present evidence that LCMV induces ROI pro-
duction during the initial phase of infection. To test the contribution
of ROI to viral infectivity, we utilized the antioxidants MnTBAP, NAC,
and Ebselen. Antioxidant treatment of cells prior to infection resulted
in decreased viral binding and growth. In contrast, antioxidant
addition at 6 h post infection resulted in a weaker inhibitory effect on
virus growth. This requirement for ROI was demonstrated in both
immortalized BHK-21 cells as well as physiologically relevant
peritoneal macrophages. Treatment of viral stocks with NEM, which
irreversibly binds to free thiols, eliminated infectious virus. Together,
these results demonstrate that ROI play an important role in virus
binding and potentially mediate thiol/disulﬁde exchange to promote
entry.
Previous studies have demonstrated that RNA viruses, such as
inﬂuenza and RSV, promote ROI generation during infection (Casola
et al., 2001; Hennet et al., 1992; Suliman et al., 2001). In this report,
we demonstrate that LCMV induces ROI production in BHK-21 cells
within 15 min of exposure. There was a subsequent decrease in ROI
by 30 min post infection before another increase at 60 min. We and
others have reported ROI generation in response to receptor binding
of growth factors, such as insulin and angiotension II (Lassegue et al.,
2001; May and de Haen, 1979), as well as for antigen speciﬁc inter-
actions with the T cell receptor (Devadas et al., 2002; Michalek et al.,
2007). LCMV binding to alpha-dystroglycan may mimic the binding
of growth factors to their cognate receptors and therefore promote
the initial wave of ROI generation observed at 15 min post infection.
In this model, the interaction between the virus and cell is initially
weak, but subsequent ROI production of membrane permeable oxi-
dants, such as H2O2, potentially strengthens the interaction through
receptor modiﬁcation. Additionally, ROI can sensitize neighboring
cells to virus binding. The results from our binding assay support this
model as antioxidant treatment decreased viral binding ten-fold.
Enveloped viruses require fusion of the viral envelope with host
cell membranes to facilitate entry. Recently, Jain et al. demonstrated
that Newcastle disease virus requires thiol/disulﬁde exchange by NDV
F (fusion) protein for virus entry (Jain et al., 2007). A similar
mechanism has also been described for HIV envelope protein, sindbis
virus, and hepatitis virus (Abell and Brown, 1993; Abou-Jaoude and
Sureau, 2007; Markovic et al., 2004). In each of these examples, thiol
modiﬁcation facilitates protein folding and fusion of the virus and cell
membranes. When we treated LCMV with NEM, which binds to free
thiols, infectious virus was eliminated within 10 min. These results
were similar to previous studies where inhibitors of cell surface thiol/
disulﬁde isomerase activity prevented virus entry and demonstrate
that LCMV requires free thiols for productive infection (Abou-Jaoude
and Sureau, 2007; Fenouillet et al., 2001; Jain et al., 2007). It should be
noted that while NDV, HIV, and hepatitis virus fuse at the cell
membrane, LCMV and sindbis virus fuse within an endosomal
membrane after acidiﬁcation of the vesicle and indicate a role for
ROI-mediated regulation of viral entry in different cell compartments
(Abell and Brown, 1993; Abou-Jaoude and Sureau, 2007; Jain et al.,
2007; Markovic et al., 2004; Quirin et al., 2008). These experimentssuggest that the ﬁrst wave of ROI production may not only strengthen
the interaction between the virus and the cell, but may also facilitate
thiol/disulﬁde exchange to permit entry. There are ﬁfteen cysteine
residues present in the glycoprotein polyprotein of LCMV Armstrong
that may be required for disulﬁde bond formation. Future studies that
ascertain the redox sensitive cysteine(s) necessary for productive
infection will shed light on the role of ROI during viral pathogenesis.
During infection, we also observed a second wave of ROI gene-
ration by 60 min. As the virus begins its intracellular lifecycle, distinct
antiviral pathways will be activated due to the presence of pathogen
associated molecular components interacting with Toll-like receptors,
protein kinase R, RIG-1, and MDA-5. In the case of RSV, ROI produced
during infection play a critical role in induction of signal transducers
and activators of transcription (STAT) activation and interferon
regulatory factor-3 (IRF-3), IRF-5, and IRF-7 gene expression in
human airway epithelial cells (Indukuri et al., 2006; Liu et al., 2004).
Viruses, such as HIV and HCV, can also harness ROI to increase viral
replication and growth (Nakamura et al., 2002; Waris et al., 2005). In
the case of HIV, increased ROI can promote NF-kB activation and
subsequent transcription of the HIV-LTR (Israel and Gougerot-
Pocidalo, 1997; Israel et al., 1992). During HCV infection, ROI can
contribute to pathology and potentially viral dissemination by
accelerating apoptosis (Irshad and Dhar, 2006; Okuda et al., 2002).
When cells were treated with antioxidants 6 h after LCMV infection,
there was aweak, but signiﬁcant decrease in virus titer. The decreased
virus growth was not a result of decreased cell growth since cell
numbers were equivalent between vehicle and MnTBAP treated
samples at 48 h. Instead, LCMV may utilize ROI production to maxi-
mize replication or egress. It is also possible that the decrease we
observe in infectious virus results from decreased re-infection of cells
in the presence of MnTBAP and decreased stability of the virus over
24 h (Fig. 7A). Further work will be required to elucidate the
intracellular stages of virus growth that utilize ROI. Together, our
results support a two-step model in which weak LCMV attachment
induces a ﬁrst wave of ROI production that strengthens virus binding,
sensitizes neighboring cells, and potentially mediates thiol/disulﬁde
exchange for entry. A second wave of ROI produced in response to
activation of intracellular innate immune defense pathways may also
enhance viral replication and growth.
In conclusion, our studies demonstrate that the generation of ROI
during LCMV infection is a critical process in promoting infectivity. ROI
produced during the initial stage of infection were essential as
antioxidant treatment decreased virus binding and growth. LCMV also
requires free thiol residues that may be necessary for membrane
fusion and entry during infection. In contrast, antioxidant addition at
6 h post infection had minimal effects on virus titer. Future studies
targeting LCMV's requirement for ROI and thiol modiﬁcation may lead
to improving treatment of related clinical human hemorrhagic fevers.
Materials and methods
Virus and BHK-21 cells
The Armstrong CA 1371 strain of LCMV (Arm-7) was used in this
study (Ahmed et al., 1984). BHK-21 cells were grown in Dulbeccos
modiﬁed Eagle's medium containing penicillin, streptomycin, L-gluta-
mine, and 5% fetal bovine serum (FBS). Vero cells were grown to
conﬂuency in minimum essential medium Eagle containing penicillin,
streptomycin, L-glutamine, and 7% fetal bovine serum. Virus titers
were determined by plaque assay on Vero cells as previously described
(Ahmed et al., 1984).
Flow cytometry
5-(and-6)-chloromethyl-2′,7′-dichlorodihydroﬂuorescein diace-
tate, acetyl ester oxidation (DCFDA)) was purchased from Invitrogen
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starved for 1 h and then mock treated or infected with LCMV in a T25
Flask (Falcon). After infection, cells were washed with PBS, trypsin
digested, and transferred to a 96 well round bottom plate. Cells were
then loaded with 5 µM DCFDA in serum free media and incubated for
30 min at 37 °C prior to being washed and resuspended in PBS.
Samples were acquired immediately on a FACSCalibur instrument and
analyzed using Flowjo software (Tree Star). Data are presented as
change in mean ﬂuorescent intensities compared to cells at t=0.
Direct staining for the detection of intracellular LCMV-NP at 24 h post
MOI of 10 infection was performed as previously described using
monoclonal mouse antibody 113 (Homann et al., 2004) and a goat-
anti-mouse IgG AlexaFluor 488 secondary antibody (Molecular
Probes).
Isolation of peritoneal macrophages
Peritoneal macrophages were isolated from naïve C57BL/6 mice as
previously described (King et al., 1990). Brieﬂy, macrophages were
isolated by peritoneal lavage with Dulbecco's phosphate buffered
saline (Hyclone). Cells were washed once with RPMI containing 10%
fetal bovine serum (FBS) and allowed to adhere for 3 h at 37 °C to
tissue culture plates. Non-adherent cells were then removed and
macrophages were washed 3 times with PBS before addition of RPMI
containing 10% FBS.
Antioxidant treatment of BHK-21 and peritoneal macrophages
Cells were pretreated with Mn (III) tetrakis (4-benzoic acid)
porphyin chloride (MnTBAP), N-acetyl cysteine (NAC), or Ebselen for
1 h. Virus was then added at an MOI of 0.1, 1 or 10 in the presence of
antioxidant and serum free media. After 1 h of infection, excess virus
was removed, cells were washed with PBS, and fresh media con-
taining antioxidant was added back. For the experiment in which
antioxidant was added at 6 h post infection, cells were infected with
LCMV for 1 h in serum free media, washed, and fresh media was
added back. At 6 h, MnTBAP was added to the media for a ﬁnal
concentration of 200 µM. At each time point post infection, super-
natants were collected and virus was titered on Vero cells.
Cell viability assay
BHK-21 cells andmacrophages were counted at time 0 or after 48 h
of incubation in the presence or absence of MnTBAP, NAC, Ebselen, and
virus at an MOI of 10. BHK-21 cells were washed with PBS, removed
from the ﬂask by trypsin digestion, and diluted in trypan blue.
Macrophages were washed once with PBS prior to being counted in
the presence of trypan blue. If cells were able to exclude trypan blue,
they were scored as viable.
LCMV binding assay
LCMV binding assay was adapted fromDe La Torre et al (de la Torre
et al., 1993). Cells were pretreated with MnTBAP or vehicle for 1 h. At
this time, ﬂasks were placed at 4 °C and virus was added at an MOI of
0.5 (volume, 1 mL). After 1 h, the monolayer was washed three times
with cold PBS, trypsinized in 0.5 mL, and PBS was added to 1 mL ﬁnal.
Lysates were then frozen at –70 °C. To titer virus, cells were ﬁrst
thawed, homogenized, and cell debris was removed by centrifugation.
Virus titers in the supernatant were then determined as described
above.
Antioxidant and N-ethyl Malemide treatment of virus stocks
For antioxidant treatment, 200 µMMnTBAP or vehicle were added
to virus stock (2×108 pfu/mL) and then incubated for a total of 24 h at37 °C. At each time point, virus was diluted 1000 fold in serum free
media. At this step, samples were incubated with 300 mM NEM or
vehicle for 10 min at room temperature. Diluted stocks were then
frozen at −70 °C and later titered on Vero cells.
Statistical analysis
Data from vehicle and treated samples were analyzed using two-
tailed Student's t test, and p≤0.05 was considered signiﬁcant.
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